The point-of-care (poc) coagulation testing market size has grown steadily in recent years. It will grow from $1.25 billion in 2025 to $1.3 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases requiring anticoagulation therapy, increasing demand for rapid coagulation results in operating rooms and icus, early clinical adoption of optical and mechanical poc testing platforms, expansion of coagulation monitoring in hospital and clinic settings, growing awareness of point-of-care diagnostics for treatment optimization.
The point-of-care (poc) coagulation testing market size is expected to see steady growth in the next few years. It will grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing shift toward decentralized and home-based coagulation monitoring, rising utilization of electrochemical detection technologies, growing procedure volumes in emergency and trauma care environments, expanding access to retail and direct tender distribution channels, rising focus on reducing turnaround time and improving therapy outcomes. Major trends in the forecast period include rising adoption of rapid bedside coagulation testing in critical and emergency care settings, increasing use of poc coagulation devices for anticoagulation therapy monitoring, growing preference for portable and handheld coagulation analyzers, expansion of coagulation testing utilization in home care and outpatient settings, increasing demand for real-time clinical decision support through near-patient testing.
The increasing incidence of cardiovascular diseases is expected to drive the growth of the point-of-care (POC) coagulation testing market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including coronary heart disease, cerebrovascular disease, and peripheral arterial disease. Point-of-care (POC) coagulation testing supports the management of cardiovascular diseases by delivering real-time insights into a patient’s coagulation status, enabling prompt clinical decision-making regarding anticoagulation therapy and helping to reduce the risk of bleeding complications following cardiac surgery. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based public health institute, in 2023, approximately one in six cardiovascular-related deaths occurred among adults younger than 65 years, with a total of 919,032 deaths attributed to cardiovascular disease, accounting for one in every three deaths. Therefore, the rising incidence of cardiovascular diseases is driving the growth of the point-of-care (POC) coagulation testing market.
Major companies operating in the point-of-care (POC) coagulation testing market are focusing on innovating connected POC coagulation solutions through strategic collaborations to gain a competitive edge. Strategic collaboration refers to a formal agreement between two or more organizations to work jointly toward shared, mutually beneficial objectives, often combining complementary technologies and expertise. In the POC coagulation testing space, such collaborations enable the integration of digital health platforms, remote monitoring, and connectivity features that enhance clinical decision-making and patient access to care. For instance, in January 2023, Jana Care, a US-based company developing biomarker assays for its proprietary digital health platform, collaborated with Roche Diagnostics, a Switzerland-based company specializing in diagnostic tests, instruments, and digital healthcare solutions. Through this collaboration, the companies aimed to develop and distribute a point-of-care blood testing platform designed to screen for chronic kidney disease and heart failure. The platform allows patients to perform blood tests at home, with results transmitted digitally for remote review by clinicians, improving accessibility, supporting timely intervention, and demonstrating how connected POC solutions can strengthen care delivery and market positioning.
In December 2023, Roche, a Switzerland-based pharmaceutical company, acquired LumiraDx Ltd. for $350 million. This acquisition enhances Roche's diagnostics portfolio, enabling more patient-centric healthcare through point-of-care solutions that cover the entire patient journey. LumiraDx Ltd., based in the UK, specializes in point-of-care coagulation testing.
Major companies operating in the point-of-care (poc) coagulation testing market are Siemens Healthcare GmbH, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation, Sysmex Corporation, IDEXX Laboratories Inc., Quidel Corporation, Werfen SA, Nihon Kohden Corporation, Horiba Ltd., Hycel, Nova Biomedical Corporation, Haemonetics Corporation, Maccura Biotechnology Co. Ltd., Helena Laboratories Corporation, Abaxis Inc., ARKRAY Inc., Radiometer Medical ApS, HemoSonics LLC, iLine Microsystems SL, Corgenix Medical Corporation, Quotient Limited, Micropoint Bioscience Inc., Beijing Succeeder Technology Inc., EKF Diagnostics Holdings plc.
North America was the largest region in the point-of-care (POC) coagulation testing market in 2025. The regions covered in the point-of-care (poc) coagulation testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care (poc) coagulation testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point-of-care coagulation testing market by increasing import and raw material costs for sensors, optical components, microelectronics, and assay reagents used across optical, mechanical, and electrochemical testing platforms, leading to higher manufacturing and procurement expenses for hospitals, clinics, and home care providers. The effects are more evident in North America, Europe, and Asia-Pacific regions that depend on cross-border sourcing of handheld analyzers, strips, and disposable cartridges distributed through direct tender and retail channels. These higher landed costs have contributed to price sensitivity and delayed device adoption in some markets; however, tariffs are also encouraging localized assembly, regional reagent manufacturing, and supplier diversification, generating selective positive outcomes for domestic production ecosystems.
The point-of-care (poc) coagulation testing market research report is one of a series of new reports that provides point-of-care (poc) coagulation testing market statistics, including point-of-care (poc) coagulation testing industry global market size, regional shares, competitors with a point-of-care (poc) coagulation testing market share, detailed point-of-care (poc) coagulation testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care (poc) coagulation testing industry. This point-of-care (poc) coagulation testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care (POC) coagulation testing is a diagnostic method that evaluates blood clotting function at or near the patient's location, rather than in a centralized lab. It provides rapid results, typically within minutes, enabling healthcare professionals to make timely treatment decisions and optimize anticoagulation therapy.
The main technologies used in POC coagulation testing are optical, mechanical, and electrochemical. Optical technology utilizes light for various applications, including data transfer, imaging, and sensing. These tests are distributed through channels such as direct tenders and retail to end-users such as hospitals, clinics, and home care settings.
The point-of-care (POC) coagulation testing market consists of revenues earned by entities by providing coagulation testing services, on-site hemostasis testing, point-of-care diagnostic services, and rapid coagulation analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care (POC) coagulation testing market also includes sales of coagulation analyzers, test strips, prothrombin time (PT) monitors, D-dimer testing devices, and point-of-care coagulation testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The point-of-care (poc) coagulation testing market size is expected to see steady growth in the next few years. It will grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing shift toward decentralized and home-based coagulation monitoring, rising utilization of electrochemical detection technologies, growing procedure volumes in emergency and trauma care environments, expanding access to retail and direct tender distribution channels, rising focus on reducing turnaround time and improving therapy outcomes. Major trends in the forecast period include rising adoption of rapid bedside coagulation testing in critical and emergency care settings, increasing use of poc coagulation devices for anticoagulation therapy monitoring, growing preference for portable and handheld coagulation analyzers, expansion of coagulation testing utilization in home care and outpatient settings, increasing demand for real-time clinical decision support through near-patient testing.
The increasing incidence of cardiovascular diseases is expected to drive the growth of the point-of-care (POC) coagulation testing market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including coronary heart disease, cerebrovascular disease, and peripheral arterial disease. Point-of-care (POC) coagulation testing supports the management of cardiovascular diseases by delivering real-time insights into a patient’s coagulation status, enabling prompt clinical decision-making regarding anticoagulation therapy and helping to reduce the risk of bleeding complications following cardiac surgery. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based public health institute, in 2023, approximately one in six cardiovascular-related deaths occurred among adults younger than 65 years, with a total of 919,032 deaths attributed to cardiovascular disease, accounting for one in every three deaths. Therefore, the rising incidence of cardiovascular diseases is driving the growth of the point-of-care (POC) coagulation testing market.
Major companies operating in the point-of-care (POC) coagulation testing market are focusing on innovating connected POC coagulation solutions through strategic collaborations to gain a competitive edge. Strategic collaboration refers to a formal agreement between two or more organizations to work jointly toward shared, mutually beneficial objectives, often combining complementary technologies and expertise. In the POC coagulation testing space, such collaborations enable the integration of digital health platforms, remote monitoring, and connectivity features that enhance clinical decision-making and patient access to care. For instance, in January 2023, Jana Care, a US-based company developing biomarker assays for its proprietary digital health platform, collaborated with Roche Diagnostics, a Switzerland-based company specializing in diagnostic tests, instruments, and digital healthcare solutions. Through this collaboration, the companies aimed to develop and distribute a point-of-care blood testing platform designed to screen for chronic kidney disease and heart failure. The platform allows patients to perform blood tests at home, with results transmitted digitally for remote review by clinicians, improving accessibility, supporting timely intervention, and demonstrating how connected POC solutions can strengthen care delivery and market positioning.
In December 2023, Roche, a Switzerland-based pharmaceutical company, acquired LumiraDx Ltd. for $350 million. This acquisition enhances Roche's diagnostics portfolio, enabling more patient-centric healthcare through point-of-care solutions that cover the entire patient journey. LumiraDx Ltd., based in the UK, specializes in point-of-care coagulation testing.
Major companies operating in the point-of-care (poc) coagulation testing market are Siemens Healthcare GmbH, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation, Sysmex Corporation, IDEXX Laboratories Inc., Quidel Corporation, Werfen SA, Nihon Kohden Corporation, Horiba Ltd., Hycel, Nova Biomedical Corporation, Haemonetics Corporation, Maccura Biotechnology Co. Ltd., Helena Laboratories Corporation, Abaxis Inc., ARKRAY Inc., Radiometer Medical ApS, HemoSonics LLC, iLine Microsystems SL, Corgenix Medical Corporation, Quotient Limited, Micropoint Bioscience Inc., Beijing Succeeder Technology Inc., EKF Diagnostics Holdings plc.
North America was the largest region in the point-of-care (POC) coagulation testing market in 2025. The regions covered in the point-of-care (poc) coagulation testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care (poc) coagulation testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point-of-care coagulation testing market by increasing import and raw material costs for sensors, optical components, microelectronics, and assay reagents used across optical, mechanical, and electrochemical testing platforms, leading to higher manufacturing and procurement expenses for hospitals, clinics, and home care providers. The effects are more evident in North America, Europe, and Asia-Pacific regions that depend on cross-border sourcing of handheld analyzers, strips, and disposable cartridges distributed through direct tender and retail channels. These higher landed costs have contributed to price sensitivity and delayed device adoption in some markets; however, tariffs are also encouraging localized assembly, regional reagent manufacturing, and supplier diversification, generating selective positive outcomes for domestic production ecosystems.
The point-of-care (poc) coagulation testing market research report is one of a series of new reports that provides point-of-care (poc) coagulation testing market statistics, including point-of-care (poc) coagulation testing industry global market size, regional shares, competitors with a point-of-care (poc) coagulation testing market share, detailed point-of-care (poc) coagulation testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care (poc) coagulation testing industry. This point-of-care (poc) coagulation testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care (POC) coagulation testing is a diagnostic method that evaluates blood clotting function at or near the patient's location, rather than in a centralized lab. It provides rapid results, typically within minutes, enabling healthcare professionals to make timely treatment decisions and optimize anticoagulation therapy.
The main technologies used in POC coagulation testing are optical, mechanical, and electrochemical. Optical technology utilizes light for various applications, including data transfer, imaging, and sensing. These tests are distributed through channels such as direct tenders and retail to end-users such as hospitals, clinics, and home care settings.
The point-of-care (POC) coagulation testing market consists of revenues earned by entities by providing coagulation testing services, on-site hemostasis testing, point-of-care diagnostic services, and rapid coagulation analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care (POC) coagulation testing market also includes sales of coagulation analyzers, test strips, prothrombin time (PT) monitors, D-dimer testing devices, and point-of-care coagulation testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Point-of-Care (POC) Coagulation Testing Market Characteristics
3. Point-of-Care (POC) Coagulation Testing Market Supply Chain Analysis
4. Global Point-of-Care (POC) Coagulation Testing Market Trends and Strategies
5. Point-of-Care (POC) Coagulation Testing Market Analysis of End Use Industries
7. Global Point-of-Care (POC) Coagulation Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Point-of-Care (POC) Coagulation Testing Total Addressable Market (TAM) Analysis for the Market
9. Point-of-Care (POC) Coagulation Testing Market Segmentation
10. Point-of-Care (POC) Coagulation Testing Market Regional and Country Analysis
11. Asia-Pacific Point-of-Care (POC) Coagulation Testing Market
12. China Point-of-Care (POC) Coagulation Testing Market
13. India Point-of-Care (POC) Coagulation Testing Market
14. Japan Point-of-Care (POC) Coagulation Testing Market
15. Australia Point-of-Care (POC) Coagulation Testing Market
16. Indonesia Point-of-Care (POC) Coagulation Testing Market
17. South Korea Point-of-Care (POC) Coagulation Testing Market
18. Taiwan Point-of-Care (POC) Coagulation Testing Market
19. South East Asia Point-of-Care (POC) Coagulation Testing Market
20. Western Europe Point-of-Care (POC) Coagulation Testing Market
21. UK Point-of-Care (POC) Coagulation Testing Market
22. Germany Point-of-Care (POC) Coagulation Testing Market
23. France Point-of-Care (POC) Coagulation Testing Market
24. Italy Point-of-Care (POC) Coagulation Testing Market
25. Spain Point-of-Care (POC) Coagulation Testing Market
26. Eastern Europe Point-of-Care (POC) Coagulation Testing Market
27. Russia Point-of-Care (POC) Coagulation Testing Market
28. North America Point-of-Care (POC) Coagulation Testing Market
29. USA Point-of-Care (POC) Coagulation Testing Market
30. Canada Point-of-Care (POC) Coagulation Testing Market
31. South America Point-of-Care (POC) Coagulation Testing Market
32. Brazil Point-of-Care (POC) Coagulation Testing Market
33. Middle East Point-of-Care (POC) Coagulation Testing Market
34. Africa Point-of-Care (POC) Coagulation Testing Market
36. Point-of-Care (POC) Coagulation Testing Market Competitive Landscape and Company Profiles
37. Point-of-Care (POC) Coagulation Testing Market Other Major and Innovative Companies
40. Point-of-Care (POC) Coagulation Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Point-of-Care (POC) Coagulation Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses point-of-care (poc) coagulation testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for point-of-care (poc) coagulation testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care (poc) coagulation testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Optical Technology; Mechanical Technology; Electrochemical Technology2) By Distribution Channel: Direct Tenders; Retail
3) By End-User: Hospitals; Clinics; Home care
Subsegments:
1) By Optical Technology: Reflectance Photometry; Fluorescence Detection; Colorimetric Detection2) By Mechanical Technology: Mechanical Oscillation; Ultrasonic Detection
3) By Electrochemical Technology: Amperometric Detection; Potentiometric Detection; Conductometric Detection
Companies Mentioned: Siemens Healthcare GmbH; Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Danaher Corporation; Sysmex Corporation; IDEXX Laboratories Inc.; Quidel Corporation; Werfen SA; Nihon Kohden Corporation; Horiba Ltd.; Hycel; Nova Biomedical Corporation; Haemonetics Corporation; Maccura Biotechnology Co. Ltd.; Helena Laboratories Corporation; Abaxis Inc.; ARKRAY Inc.; Radiometer Medical ApS; HemoSonics LLC; iLine Microsystems SL; Corgenix Medical Corporation; Quotient Limited; Micropoint Bioscience Inc.; Beijing Succeeder Technology Inc.; EKF Diagnostics Holdings plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Point-of-Care (POC) Coagulation Testing market report include:- Siemens Healthcare GmbH
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Sysmex Corporation
- IDEXX Laboratories Inc.
- Quidel Corporation
- Werfen SA
- Nihon Kohden Corporation
- Horiba Ltd.
- Hycel
- Nova Biomedical Corporation
- Haemonetics Corporation
- Maccura Biotechnology Co. Ltd.
- Helena Laboratories Corporation
- Abaxis Inc.
- ARKRAY Inc.
- Radiometer Medical ApS
- HemoSonics LLC
- iLine Microsystems SL
- Corgenix Medical Corporation
- Quotient Limited
- Micropoint Bioscience Inc.
- Beijing Succeeder Technology Inc.
- EKF Diagnostics Holdings plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.3 Billion |
| Forecasted Market Value ( USD | $ 1.52 Billion |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
